Renal Imaging Strategies Put to the Test
Noncontrast MRI technique evaluates renal tumor characterization in rapid acquisition.
By
Kathryn Wighton
March 23, 2026
Clinical Scorecard: Renal Imaging Strategies Put to the Test
At a Glance
Category Detail
Condition Renal Neoplasms Key Mechanisms Magnetic resonance fingerprinting (MRF) for T1 and T2 relaxation time analysis Target Population Adults with suspected renal cell carcinoma Care Setting Prospective study in a clinical radiology setting
Key Highlights
MRF-derived T1 and T2 relaxation times achieved an AUC of 0.89 for differentiating tumor aggressiveness. T2 relaxation time provided the strongest discrimination between indolent and aggressive tumors. The study involved 24 adult patients with histopathologically confirmed renal neoplasms. MRF allows simultaneous acquisition of T1 and T2 in a single breath hold. Limitations include small sample size and potential selection bias. Guideline-Based Recommendations
Diagnosis
Use MRF-derived T1 and T2 relaxation times for noninvasive differentiation of renal tumors. Management
Consider MRF imaging in the evaluation of renal neoplasms. Monitoring & Follow-up
Monitor T1 and T2 values to assess tumor characteristics over time. Risks
Potential selection bias and technical challenges in aligning imaging data. Patient & Prescribing Data
Adults with renal neoplasms confirmed by histopathologic grading.
MRF may provide complementary information for treatment planning.
Clinical Best Practices
Incorporate MRF imaging in the diagnostic workup of renal tumors. Utilize T2 relaxation time as a key metric for tumor characterization. Related Resources & Content
